middle.news
Saluda Medical Posts 28% Revenue Growth and FDA Approval of CAP24 Paddle Lead
8:21am on Friday 28th of August, 2026 AEST
•
Healthcare
Read Story
Saluda Medical Posts 28% Revenue Growth and FDA Approval of CAP24 Paddle Lead
8:21am on Friday 28th of August, 2026 AEST
Key Points
FY26 revenue up 28% to US$90.2 million, exceeding guidance
Gross margin expands 230 basis points to 48.9%
Adjusted EBITDA loss widens to US$113.7 million
FDA approves CAP24 paddle lead, expanding US market reach
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Saluda Medical, (ASX:SLD)
OPEN ARTICLE